Lee S S, Jang J J, Cho K J, Khang S K, Kim C W
Department of Pathology, Korea Cancer Center Hospital, Seoul, Korea.
Histopathology. 1997 Mar;30(3):234-42. doi: 10.1046/j.1365-2559.1997.d01-605.x.
We examined 81 cases of primary gastrointestinal lymphomas in Korea, including 64 gastric lymphomas and 17 intestinal lymphomas, for EBV expression by EBER-1 in situ hybridization (ISH) and EBNA-1 PCR. In EBER-1 positive cases, we performed immunohistochemistry for latent membrane protein-1 (LMP-1) and EBV diffuse early antigen (EA(D)) to compare EBV latent gene expression and lytic process. EBER-1 was detected in 15 of 81 cases of lymphomas. EBER-1 expression showed three different patterns on tumour cells; diffuse 4/81 (5%), localized 4/81 (8%), and a few scattered pattern 7/81 (9%). We regarded diffuse pattern and localized pattern as EBER-1 positive group (8/81: 10%). Diffuse pattern of EBER-1 was shown in all three T-cell lymphomas and one B-cell lymphoma. A localized pattern was seen all in B-cell lymphomas. The EBER-1 expression was 11% in the stomach (7/64) and 6% in the intestine (1/17). Five of the eight EBER-1 positive gastric lymphomas were histologically diffuse large B-cell lymphomas, and the other three were peripheral T-cell lymphoma, unspecified, one angiocentric lymphoma, and one intestinal T-cell lymphoma by REAL classification. Eight MALT type gastric B-cell lymphomas showed no EBV association. EBV nuclear antigen (EBNA-1) was detected in 15 of 45 resected cases (33%) by PCR. EBER-1 positive cases were all EBNA-1 positive. Twelve EBNA-positive/EBER-negative cases consisted of seven cases showing a few scattered EBER-1 positive lymphocytes. LMP-1 and diffuse early antigen (EA(D)) was detected in five and three cases, respectively. Although follow-up information in our series was incomplete, it seemed that there was no significant difference in their staging or prognosis between EBER-positive cases and EBER-negative group. It is concluded that EBV is associated with some lymphomas among Koreans without overt pre-existing immunodeficiency, especially in T-cell lymphomas.
我们通过EBER-1原位杂交（ISH）和EBNA-1聚合酶链反应（PCR）检测了韩国的81例原发性胃肠道淋巴瘤，其中包括64例胃淋巴瘤和17例肠道淋巴瘤的EBV表达情况。在EBER-1阳性病例中，我们进行了潜伏膜蛋白-1（LMP-1）和EBV弥漫性早期抗原（EA(D)）的免疫组织化学检测，以比较EBV潜伏基因表达和裂解过程。在81例淋巴瘤病例中，有15例检测到EBER-1。EBER-1在肿瘤细胞上呈现三种不同的模式：弥漫性4/81（5%）、局限性4/81（8%）和散在少数细胞模式7/81（9%）。我们将弥漫性模式和局限性模式视为EBER-1阳性组（8/81：10%）。所有3例T细胞淋巴瘤和1例B细胞淋巴瘤均呈现EBER-1弥漫性模式。局限性模式均见于B细胞淋巴瘤。EBER-1在胃中的表达率为11%（7/64），在肠道中的表达率为6%（1/17）。8例EBER-1阳性胃淋巴瘤中，5例组织学类型为弥漫性大B细胞淋巴瘤，另外3例根据REAL分类为未特定的外周T细胞淋巴瘤、1例血管中心性淋巴瘤和1例肠道T细胞淋巴瘤。8例MALT型胃B细胞淋巴瘤未显示与EBV相关。通过PCR在45例切除病例中的15例（33%）检测到EBV核抗原（EBNA-1）。EBER-1阳性病例均为EBNA-1阳性。12例EBNA阳性/EBER阴性病例中，有7例显示少数散在的EBER-1阳性淋巴细胞。分别在5例和3例中检测到LMP-1和弥漫性早期抗原（EA(D)）。尽管我们系列研究中的随访信息不完整，但EBER阳性病例和EBER阴性组在分期或预后方面似乎没有显著差异。结论是，在没有明显既往免疫缺陷的韩国人中，EBV与某些淋巴瘤相关，尤其是在T细胞淋巴瘤中。
